Angiotensin Receptor Blockers (ARBs)

The Real-world Use of Benefit-unproven ARBs in HFrEF: Clinical Outcomes andPrescrip on Pa erns

by Prateek Chopra | May 29, 2026 | Cardiology Conferences | ESC-HF 2026 In the contemporary management of heart failure with reduced ejection fraction (HFrEF; LVEF <40%), angiotensin II receptor blockers (ARBs) remain widely prescribed despite the increasing use of angiotensin receptor–neprilysin inhibitors. While valsartan, candesartan, and losartan have established clinical benefit in HFrEF, the outcomes associated with other ARBs remain […]

The Real-world Use of Benefit-unproven ARBs in HFrEF: Clinical Outcomes andPrescrip on Pa erns Read Post »

Leave a Comment / ESC-HF Day 3 / / / , , , ,

Clinical Decision Making in Hypertension Management: MatchingPharmacology to Patient Profile

by Prateek Chopra | June 6, 2026 | Cardiology Conferences | ESH 2026 Unmet Need in Hypertension: Hypertension affects over 1.3 billion individuals worldwide and remains the leading modifiable risk factor for cardiovascular morbidity and mortality. Despite numerous pharmacological options, BP control rates are suboptimal, highlighting the gap between available therapies and individualized patient management. Tailoring therapy to patient-specific characteristics, including

Clinical Decision Making in Hypertension Management: MatchingPharmacology to Patient Profile Read Post »

Leave a Comment / ESH Day 2 / / / , , , ,
Scroll to Top